Sexual dysfunction associated with antidepressant drugs
Sexual dysfunction associated with antidepressant drugs
The term ‘sexual dysfunction’ describes a disturbance in sexual desire and the psychophysiological changes that characterise the normal sexual response cycle, and cause marked personal distress and interpersonal difficulty. Epidemiological studies indicate that sexual dysfunction is common in the general population, but more common in depressed individuals in community settings and clinical samples. Most antidepressant drugs have adverse effects on sexual function, but accurate identification of the incidence of treatment-emergent dysfunction has proved troublesome. Furthermore, investigations of sexual dysfunction associated with antidepressants have one or more methodological flaws. There may be some advantages for bupropion, moclobemide, nefazodone and reboxetine over other antidepressants. Many approaches have been adopted for management of patients with sexual dysfunction associated with antidepressant treatment, including waiting for the problem to resolve, behavioural strategies to modify sexual technique, individual and couple psychotherapy, delaying the intake of antidepressants until after sexual activity, reduction in daily dosage, ‘drug holidays’, use of adjuvant treatments, and switching to a different antidepressant.
antidepressants, bupropion, mirtazapine, moclobemide, monoamine oxidase inhibitors (MAOIs), nefazodone, reboxetine, selective serotonin re-uptake inhibitors (SSRIs), sexual dysfunction, tricyclic antidepressants (TCAs)
457-470
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
2004
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Baldwin, David S.
(2004)
Sexual dysfunction associated with antidepressant drugs.
Expert Opinion on Drug Safety, 3 (5), .
(doi:10.1517/14740338.3.5.457).
Abstract
The term ‘sexual dysfunction’ describes a disturbance in sexual desire and the psychophysiological changes that characterise the normal sexual response cycle, and cause marked personal distress and interpersonal difficulty. Epidemiological studies indicate that sexual dysfunction is common in the general population, but more common in depressed individuals in community settings and clinical samples. Most antidepressant drugs have adverse effects on sexual function, but accurate identification of the incidence of treatment-emergent dysfunction has proved troublesome. Furthermore, investigations of sexual dysfunction associated with antidepressants have one or more methodological flaws. There may be some advantages for bupropion, moclobemide, nefazodone and reboxetine over other antidepressants. Many approaches have been adopted for management of patients with sexual dysfunction associated with antidepressant treatment, including waiting for the problem to resolve, behavioural strategies to modify sexual technique, individual and couple psychotherapy, delaying the intake of antidepressants until after sexual activity, reduction in daily dosage, ‘drug holidays’, use of adjuvant treatments, and switching to a different antidepressant.
This record has no associated files available for download.
More information
Published date: 2004
Keywords:
antidepressants, bupropion, mirtazapine, moclobemide, monoamine oxidase inhibitors (MAOIs), nefazodone, reboxetine, selective serotonin re-uptake inhibitors (SSRIs), sexual dysfunction, tricyclic antidepressants (TCAs)
Identifiers
Local EPrints ID: 27523
URI: http://eprints.soton.ac.uk/id/eprint/27523
ISSN: 1474-0338
PURE UUID: 85fdb0bc-677b-4718-921f-9727eb2399b0
Catalogue record
Date deposited: 26 Apr 2006
Last modified: 16 Mar 2024 02:48
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
